Tagged with EU

Switzerland Although the global biotech sector is currently struggling with equity and debt financing, Swiss biotech is on the up. 2023 saw the Swiss biotech sector hit record revenues of CHF 7.3 billion (EUR 7.8 billion) with capital investments surpassing CHF 2 billion. While funding inflows still did not reach the…

China Vincent Chan, VP and GM of bioMérieux Greater China, shares insights into how the microbiology diagnostics company’s presence has evolved in China over the course of 30 years to today serve some 4,000 hospitals across the country. He walks us through the government measures that have prioritized microbiology testing to…

Switzerland Dominik Escher, Managing Partner of Pureos Bioventures explores the firm’s strategic focus on drug development, particularly in biologics and antibody-based therapeutics. With a keen emphasis on the Swiss biotech ecosystem, Escher discusses the firm’s investment approach and its commitment to fostering innovation in Europe and beyond.   Swiss biotech stands…

Switzerland Emanuele Ostuni, CEO of ARTBIO, delves into the company’s innovative approach to radioligand therapies, focusing on its potential to replace chemotherapy and provide more effective treatment options for patients. Ostuni emphasizes the company’s commitment to precision oncology, with a strong team spread across Switzerland, Norway, USA, and the UK.  …

France A roundup of the top stories coming out of France’s pharma industry, including Sanofi’s consumer health unit spinout and EUR 40 million investment in antibody bioproduction; the French govenment’s unprecedented deal with Upsa; the Health Minister’s plans to lower the national social security system’s reimbursement of drugs; Servier’s newfound willingness…

Switzerland Marianthi Psaha, President, Head of EMEA for Santen, discusses the company’s journey towards becoming a specialized leader in ophthalmology—highlighting how digital transformation, innovation in myopia treatment, and strategic partnerships are reshaping its impact on eye health across Europe. Psaha delves into the challenges of building awareness of the area’s importance…

Global With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk may lead the charge, but other contenders are looking to get a piece of this lucrative market as the two…

Switzerland Europe and Canada (EUCAN) have an essential role in Takeda’s global mission to advance healthcare innovation. Ricardo Marek, President of Takeda’s EUCAN division, discusses the operational and regulatory challenges, the importance of Switzerland as a strategic base, and Takeda’s post-Shire acquisition growth strategy.   Europe is central not just as…

Switzerland Bachem’s Thomas Meier highlights the company’s pivotal role as a CDMO in the rapidly evolving peptide and oligonucleotide markets, emphasizing strategic expansions, innovative manufacturing techniques, and a deep commitment to sustainability. With a vision for growth that includes both profitability and operational excellence, Bachem is poised to lead in therapeutic…

Switzerland Hendrik von Waldburg, Country Manager of Angelini Pharma S.p.A., Rom, Zweigniederlassung Zug, shares insights into the company’s ambitious vision for brain health and its expanding presence in the Swiss market. With a strong background in CNS and a focus on innovative therapies, Hendrik discusses the challenges and opportunities of building…

Spain A roundup of some of the top stories coming out of Spain’s life sciences sector, including Brookfield’s ongoing interest in Grifols; Rovi’s change of heart about selling its CDMO business; Reig Jofre’s partnership with startup DyCare for an AI-powered digital rehabilitation platform; Almirall’s European filing for its triazole antifungal compound;…

UK Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional cash to R&D, and incentivise manufacturing through a new GBP 520 million Life Sciences Innovative Manufacturing Fund (LSIMF).   Addressing…